کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5525242 1546666 2017 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Mini-reviewTargeting EGFRvIII for glioblastoma multiforme
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Mini-reviewTargeting EGFRvIII for glioblastoma multiforme
چکیده انگلیسی


- Targeting EGFRvIII using CAR T-cell therapy.
- The role of EGFRvIII specific therapeutic vaccine in GBM.
- Preclinical and clinical findings of antibodies against EGFRvIII for treating GBM.
- Preclinical findings of Bi-specific T-Cell Engager targeting EGFRvIII for GBM.

Glioblastoma multiforme (GBM) is the most progressive primary brain tumor. Targeting a novel and highly specific tumor antigen is one of the strategies to overcome tumors. EGFR variant III (EGFRvIII) is present in 25%-33% of all patients with GBM and is exclusively expressed on tumor tissue cells. Currently, there are various approaches to target EGFRvIII, including CAR T-cell therapy, therapeutic vaccines, antibodies, and Bi-specific T Cell Engager. In this review, we focus on the preclinical and clinical findings of targeting EGFRvIII for GBM.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cancer Letters - Volume 403, 10 September 2017, Pages 224-230
نویسندگان
, , ,